Neumora Therapeutics, Inc. (NMRA)
(Delayed Data from NSDQ)
$1.46 USD
-0.19 (-11.52%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $1.50 +0.04 (2.74%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NMRA 1.46 -0.19(-11.52%)
Will NMRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NMRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NMRA
JNJ Halts Development of Depression Drug Over Efficacy Concerns
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More
NMRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neumora Stock Hits Record Low on Depression Drug Study Failure
Other News for NMRA
Neumora outlines six upcoming clinical catalysts and prioritizes obesity program with NMRA-215
Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript
Q2 2025 Neumora Therapeutics Inc Earnings Call Transcript
Neumora Therapeutics GAAP EPS of -$0.33
Neumora Therapeutics reports Q2 EPS (33c), consensus (37c)